Supplemental material
Report
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries
Andre Azevedo Reis Teixeiraa New Mexico Consortium, Los Alamos, NM, USA
https://orcid.org/0000-0002-8348-0235View further author information
https://orcid.org/0000-0002-8348-0235View further author information, Michael Frank Erasmusb Specifica Inc, Santa Fe, NM, USAhttps://orcid.org/0000-0002-8046-5048View further author information
https://orcid.org/0000-0002-8046-5048View further author information, Sara D’Angelob Specifica Inc, Santa Fe, NM, USAhttps://orcid.org/0000-0002-8329-9938View further author information
https://orcid.org/0000-0002-8329-9938View further author information, Leslie Naranjob Specifica Inc, Santa Fe, NM, USAhttps://orcid.org/0000-0003-2165-0814View further author information
https://orcid.org/0000-0003-2165-0814View further author information, Fortunato Ferrarab Specifica Inc, Santa Fe, NM, USAhttps://orcid.org/0000-0002-4615-035XView further author information
https://orcid.org/0000-0002-4615-035XView further author information, Camila Leal-Lopesa New Mexico Consortium, Los Alamos, NM, USAhttps://orcid.org/0000-0001-7058-3350View further author information
https://orcid.org/0000-0001-7058-3350View further author information, Oliver Durrantc UCB Pharma Ltd, Slough, UKhttps://orcid.org/0000-0003-3183-7025View further author information
https://orcid.org/0000-0003-3183-7025View further author information, Cecile Galmichec UCB Pharma Ltd, Slough, UKhttps://orcid.org/0000-0002-4866-0484View further author information
https://orcid.org/0000-0002-4866-0484View further author information, , & Andrew Raymon Morton Bradburyb Specifica Inc, Santa Fe, NM, USACorrespondence[email protected]
https://orcid.org/0000-0002-5567-8172View further author information
https://orcid.org/0000-0002-5567-8172View further author information show all